Preventing unplanned “whoops” sarcoma surgery: from technical pearls to early referral and network-level quality metrics

Novelty and contribution of this review

Unplanned (“whoops”) excision has been discussed for decades; the added value of this review is not the diagnosis of the problem, but the operationalization of prevention across levels of care. Building on the technical prevention principles summarized by Wise et al. (1), we synthesize (I) upstream diagnostic and referral failure points; (II) hub-and-spoke implementation steps that make the safe pathway the default; and (III) a compact set of measurable network quality indicators [including the rate of non-oncologic-intent excision and local recurrence (LR)] to enable audit-and-feedback. We additionally clarify the case-mix paradox—why survival may appear similar despite higher LR risk after unplanned excision—to avoid misinterpretation that could normalize preventable harm. Finally, we use a behavior-change framework to specify practical levers for changing clinician behavior and reducing friction in referral, imaging, biopsy, and multidisciplinary team (MDT) access.

What Wise et al. (1) add

Wise et al. provide a clear clinical map for avoiding preventable harm when a lump might be sarcoma (1). Their advice is practical and appropriately conservative: obtain cross-sectional imaging before any incision—with magnetic resonance imaging (MRI) preferred for extremity/trunk masses given its superiority for compartment mapping; secure tissue diagnosis ahead of surgery, ideally with a planned core needle biopsy under image guidance; and plan longitudinal, extensile incisions that respect compartments and can be widened during definitive resection. They caution against in-clinic “snip” excisions, highlight judicious use (or avoidance) of tourniquets and drains that may seed compartments, and, most importantly, emphasize the early recognition of red flags that should trigger referral rather than excision. The paper’s strength lies in operational clarity for generalists and non-sarcoma subspecialists in secondary care, where many preventable errors arise. It addresses the exact points of failure that convert a potentially straightforward, oncologically planned procedure into a complex salvage scenario. In short: it offers actionable guardrails at the coalface—what to do, what not to do, and when to stop and call.

Why prevention must be system-level, not just surgical

Yet even perfect intraoperative checklists cannot compensate if patients enter the wrong pathway. Regional analyses from specialized networks show that fragmented care pathways—in which diagnosis and/or initial management occur outside sarcoma centers—are associated with more unplanned excisions, higher positive-margin rates, and increased LR risk compared with comprehensive, integrated pathways (2). This establishes a direct link between the location and timing of early decisions and downstream oncologic outcomes. It also reframes prevention as something that starts before the operating room: with triage rules, access to expert advice, and fast channels for referral and biopsy planning. The index article’s technical pearls are therefore necessary and provide a valuable base. Without system-level controls however, the same errors recur—only earlier—because non-specialist settings are not equipped or incentivized to resist intuitive, “let’s just remove it” impulses. Prevention, in other words, is an organizational property as much as a surgical one.

Where the pathway goes wrong—and who is at risk

The diagnostic journey to a sarcoma diagnosis has two particularly fragile segments (3,4). First is the patient interval, essentially the preclinical phase, during which slow-growing or painless lesions can be minimized or misinterpreted, delaying first presentation. Second—and most actionable—is the secondary-care interval, where time pressure, accessibility of minor procedures, and anchoring on “benign-appearing” features can lead to unplanned excision. A small, consistent set of probability cues should short-circuit that reflex: size ≥5 cm, deep to fascia, progressive growth, axial location (trunk/proximal limb/pelvis), and pain at rest or at night. When one or more of these cues are present, the default should be a standardized sequence: MRI → planned image-guided core biopsy (coordinated with the surgical team that may later perform definitive resection to avoid contamination and cellular dissemination) → early MDT input, not excision. Network pathway work shows that delays and mis-triage cluster precisely in these contexts—older age, axial site, and deeper or larger masses—making explicit, universal “do-not-excise” rules at spoke facilities essential. The translation step matters: build these triggers into referral templates, order sets, electronic pathways, and standing slots for expedited MRI/biopsy at the hub. When these steps are implemented, adherence to Wise et al.’s recommendations no longer depend on the individual attentiveness of each clinican (1). Instead, they become embedded as default processes in the system, making the safe pathway automatic rather than optional.

Practical note for clinicians: the moment a mass meets the above red-flag profile, “quick excision” is not the shortcut—fast referral is. Explicitly communicating this in discharge instructions, General Practioner (GP) letters, and outpatient clinic signage (e.g., “Large or deep soft-tissue masses? MRI first, biopsy second—do not excise”) reduces ambiguity. In parallel, hubs can designate a single contact pathway (one phone/email) for expedited advice and scheduling, lowering friction for referrers. The goal is to make the safest option also the easiest.

Reconciling LR and survival—the case-mix paradox

A recurring source of confusion in sarcoma quality discussions is the observation that unplanned excisions increase the risk of LR, but at the same time survival outcomes [metastasis-free survival (MFS) or overall survival (OS)] may appear similar to those after planned resections. In Swiss Sarcoma Network (SSN) real-world cohorts, LR was 24.5% after unplanned resections versus 17.3% after planned resections, and 32.6% in fragmented care pathways versus 13.1% in comprehensive pathways. Target-trial-style and comparative analyses help explain this paradox: case mix differs (5). Unplanned cohorts often contain a higher proportion of smaller, superficial, or lower-grade tumors—lesions that presented as deceptively “benign”—whereas planned cohorts in specialist centers naturally include more large, deep, or high-grade sarcomas with worse baseline prognosis (6). In this situation, survival parity reflects selection, not safety. Interpreting it at face value risks normalizing preventable harm, because LR after an unplanned excision carries real morbidity: re-excision of contaminated planes, unplanned radiotherapy trade-offs, more complex reconstruction, potential functional compromise, and psychological burden. The appropriate conclusion is not tolerance of whoops resections, but renewed emphasis on prevention and centralization. Definitive surgery should occur once, in the right hands, with margins planned from the outset. Recognizing the case-mix paradox is therefore a critical communication task for networks and tumor boards; it aligns surgeon intuitions, managerial metrics, and patient messaging around the true goal—fewer whoops, fewer re-excisions, fewer LRs.

Turning advice into a default pathway

Wise et al. detail how non-oncologic resections happen (1); pathway analyses clarify why they keep happening: non-specialist settings lack standardized triage, rapid access to MDT advice, and friction-free referral slots (2). The corrective is straightforward and scalable across diverse health systems:

• Publish referral triggers where they are needed—on clinic walls, order sets, and intranet landing pages at spoke sites. Use plain language (“≥5 cm, deep, growing, axial, pain at night → MRI + core biopsy → call MDT”).
• Require pre-incision MRI and planned core biopsy for any red-flag mass. Ultrasound may be adjunctive, but it cannot substitute for MRI in mapping compartments for surgical planning. Make deviation require documentation (and ideally pre-approval).
• Create a fast MDT callback channel at the hub (e.g., response within 72 hours) with named contacts. Provide standing imaging/biopsy slots reserved for referred red-flag cases to avoid scheduling gridlock.
• Build simple electronic health record (EHR) prompts: typing “soft-tissue mass” should trigger MRI, biopsy, MDT suggestion and warn against excision.

Once these steps are baked into electronic pathways and operational schedules, doing the right thing is quicker than doing the risky thing. This is the essence of prevention at scale: align workflows so that system design supports clinician judgment, rather than relying on heroics to overcome friction.

From clinic to network: hub-and-spoke with measurable quality

A hub-and-spoke model operationalizes prevention across regions and payers (7). Hubs define rapid referral and biopsy plans, own MDT triage, steward pathology and radiology quality, and benchmark performance. Spokes screen for red flags, avoid excision, and escalate promptly. To convert good intentions into durable change, networks should report a compact set of quality indicators that clinicians recognize and managers can act on:

• Negative indicator: rate of non-oncologic-intent excision among all newly diagnosed sarcoma patients in the catchment (or, more ambitiously, among all biopsied/operated suspicious masses).
• Surgical planning: margin status at definitive resection (R0/R1) stratified by planned vs. unplanned pathway.
• Timeliness: time-to-diagnosis and time-to-first MDT from first specialist contact.
• Oncologic outcome: LR rate at 2–3 years (acknowledging histotype heterogeneity).

Real-world-time data platforms allow near-real-time dashboards with site-level feedback and risk-adjusted comparisons (8,9). Two practical tips matter here. First, keep the set small—over-reporting dilutes attention. Second, close the loop: whenever a spike in unplanned excisions or LR is detected, pair the metric with targeted education (brief case reviews, reminder flyers, pathway refreshers) and operational fixes (e.g., more reserved imaging slots). When clinicians see that metrics lead to support, not blame, adherence rises. Over time, publishing network-wide data normalizes prevention as a shared standard, not a single center’s idiosyncrasy. Importantly, the most effective approach is a collaborative structure in which referring physicians are actively included and supported in doing the right thing—recognizing red flags and referring promptly when necessary.

Why quick excisions persist—and how to change them [surgeon’s view; capability, opportunity, motivation → behavior (COM-B)]

Where ‘whoops’ resections occur and why

Unplanned excisions occur predominantly in non-oncologic-intent settings, most commonly general orthopedics/trauma and general surgery, with variable additional contributions from plastic surgery and site-specific services; a relevant share occurs in outpatient/office environments. The core mechanism is low initial suspicion (“benign lump”), leading to incision without MRI and biopsy. Countermeasures are therefore pathway-based: red-flag referral triggers, MRI-before-incision, planned core biopsy with MDT review, and audit/feedback using the non-oncologic-intent excision rate as a quality indicator.

From a surgeon’s vantage, an apparently “benign” lump seen in a packed clinic invites fast, familiar moves (10). Under time pressure, anchoring on “lipoma”, premature closure, availability bias (most lumps really are benign), and commission bias (doing something now feels safer than waiting) nudge toward same-day excision (11,12). That psychology meets a friction asymmetry: access to a minor list is immediate, while arranging MRI, image-guided core biopsy, pre-authorization, and MDT scheduling can be slow and uncertain (13). Add patient expectations (“can’t you just take it out?”), medico-legal anxiety about “missing cancer”, and—depending on the system—reimbursement and throughput metrics that reward procedures but not deliberation. Good people, in other words, are being pulled by predictable forces. Accordingly, evidence-based behavior-change techniques—brief education, electronic decision aids/clinical decision support, audit-and-feedback, and peer modeling—offer practical levers to counter these tendencies (14).

The COM-B framework clarifies what to change. Because healthcare infrastructure varies, the “MDT advice within 72 hours” should be understood as an aspirational benchmark for mature networks; in heterogeneous or resource-limited settings, the transferable minimum is a red-flag triage that prioritizes imaging and planned core biopsy and avoids diagnostic excision before staging. For capability, provide micro-teaching on red-flag probability cues and biopsy-tract planning, and give clinicians a short patient script: “the fastest path to certainty is MRI, then a core biopsy, with MDT advice within 72 hours”. For opportunity, make the right path easier than excision: build EHR defaults that auto-order MRI + core biopsy and trigger an e-MDT consult; introduce a gentle soft-stop that asks for justification before booking excision of a red-flag mass; protect reserved imaging/biopsy slots and streamline pre-auth; and offer a single, responsive hub contact. For motivation, show site-level feedback (whoops rate, R0 at definitive surgery, time-to-MDT), use peer comparison, and recognize zero-whoops spokes. Where feasible, pay for triage and MDT participation, not only cutting. Finally, adopt safe-harbor language in local policy (“adherence to the red-flag pathway constitutes standard of care”), so surgeons feel protected when they choose to refer. The practical aim is simple: referral becomes the default, excision the exception whenever sarcoma probability is non-trivial (15).

A practical call to action

The synthesis is straightforward: marry the technical pearls of the index article with system discipline so that prevention is not merely recommended—it is expected and measured (Figure 1). Concretely:

• At the spoke: institute visible referral triggers; discourage “quick excisions”; pre-populate MRI and core-biopsy orders for red-flag lesions; and post a single MDT contact pathway.
• At the hub: guarantee ≤72-hour MDT advice for red-flag referrals; protect imaging and biopsy slots; standardize biopsy technique and tract planning to avoid contaminating future resection fields; and provide quarterly feedback on whoops and LR.
• At the network level: adopt a minimal quality indicator (QI) set (non-oncologic-intent excision rate, margins, timeliness, LR), publish comparisons transparently, and make supportive adjustments where drift is seen.

Figure 1 Preventing ‘whoops’ sarcoma surgery from clinic to network (1-7). (A) Red-flag cues (≥5 cm, deep to fascia, progressive growth, axial location, pain at rest/night ± neuro deficit) should not trigger excision; default is MRI → planned image-guided core biopsy → MDT ≤72 h. (B) Default pathway: red-flag identification, MRI, core biopsy, MDT review/staging, hub surgical plan (including biopsy-tract planning, margins, reconstruction), R0 resection at hub, and adjuvant plan as indicated. Case-mix paradox: whoops LR↑, while survival parity can reflect selection bias; prevention remains essential. (C) Network quality indicators: % non-oncologic-intent excisions (negative indicator), margin status at definitive surgery, time-to-diagnosis & time-to-first MDT (from first specialist contact), and 2–3-year LR rates. (D) Hub-and-spoke escalation normalizes early referral and rapid MDT access. LR, local recurrence; MDT, multidisciplinary team; MRI, magnetic resonance imaging; QI, quality indicator; RT, radiation therapy.

When prevention becomes a network quality metric, unplanned sarcoma resections become rare events—and salvage surgery the exception rather than the plan. This is how surgical prudence becomes regional reliability: by making the safest decision the fastest, the easiest, and the most visible one for every clinician who might touch a sarcoma patient’s journey.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Chinese Clinical Oncology. The article has undergone external peer review.

Peer Review File: Available at https://cco.amegroups.com/article/view/10.21037/cco-25-122/prf

Funding: None.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://cco.amegroups.com/article/view/10.21037/cco-25-122/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Wise CE, Le C, Pham NS, et al. Prevention in non-oncologic intent sarcoma surgery. Surg Oncol 2025;62:102273. [Crossref] [PubMed]
2. Schärer M, Hösli P, Heesen P, et al. Integrated Care in Specialized Networks: Leveraging Early Referrals to Reduce Local Recurrence in Soft Tissue Sarcoma. Cancers (Basel) 2024;16:3616. [Crossref] [PubMed]
3. Elyes M, Heesen P, Schelling G, et al. Enhancing Healthcare for Sarcoma Patients: Lessons from a Diagnostic Pathway Efficiency Analysis. Cancers (Basel) 2023;15:4892. [Crossref] [PubMed]
4. Elyes M, Heesen P, Schelling G, et al. Pain Accelerates, Swelling and Sensory Disturbances Delay Diagnosis in Mesenchymal Tumors. Cancers (Basel) 2025;17:510. [Crossref] [PubMed]
5. Obergfell TTAF, Nydegger KN, Heesen P, et al. Improving Sarcoma Outcomes: Target Trial Emulation to Compare the Impact of Unplanned and Planned Resections on the Outcome. Cancers (Basel) 2024;16:2443. [Crossref] [PubMed]
6. Nydegger KN, Obergfell TTAF, Heesen P, et al. Planned and Unplanned Sarcoma Resections: Comparative Analysis of Local Recurrence, Metastasis, and Mortality. Cancers (Basel) 2024;16:3408. [Crossref] [PubMed]
7. Fuchs B, Gronchi A. Beyond the sarcoma center: establishing the Sarcoma HASM network-a Hub and Spoke Model network for global integrated and precision care. ESMO Open 2024;9:103734. [Crossref] [PubMed]
8. Fuchs B, Schelling G, Elyes M, et al. Unlocking the Power of Benchmarking: Real-World-Time Data Analysis for Enhanced Sarcoma Patient Outcomes. Cancers (Basel) 2023;15:4395. [Crossref] [PubMed]
9. Fuchs B, Heesen P. Data-Driven Defragmentation: Achieving Value-Based Sarcoma and Rare Cancer Care Through Integrated Care Pathway Mapping. J Pers Med 2025;15:203. [Crossref] [PubMed]
10. Kahneman D. Thinking, Fast and Slow. New York: Farrar, Straus and Giroux; 2011.
11. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement Sci 2012;7:37. [Crossref] [PubMed]
12. Berridge KC. From prediction error to incentive salience: mesolimbic computation of reward motivation. Eur J Neurosci 2012;35:1124-43. [Crossref] [PubMed]
13. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci 2011;6:42. [Crossref] [PubMed]
14. Michie S, Richardson M, Johnston M, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Ann Behav Med 2013;46:81-95. [Crossref] [PubMed]
15. Mitchell AP, Trivedi NU, Gennarelli RL, et al. Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review. Ann Intern Med 2021;174:353-61. [Crossref] [PubMed]